Cullinan Therapeutics (CGEM) recently saw a stock price pullback, which is viewed as a good entry point before upcoming clinical updates scheduled for December 2026. The company is developing targeted treatments for cancer and autoimmune diseases, with promising early results for its CLN-978 therapy. The combined data from CLN-978 could confirm earlier positive findings and expand its use to more patients with manageable safety, potentially improving efficacy through repeat dosing. Additionally, the pending FDA decision on zipalertinib for previously treated disease could open further opportunities if first-line approval is granted. These clinical catalysts support a "Buy" rating on CGEM at current levels, with sufficient runway to reach these milestones.
Cullinan Therapeutics' recent stock pullback is noted here alongside Pluang's health sector snapshot as of Sep 29, 2026 18:14 WIB. Of 100 health-sector US stocks on Pluang, 44 rose and 49 fell today. GeneDx Holdings Corp (WGS) saw a full buy order activity with a price of USD 84.75 and a 1-day change of -1.37%, contrasting with AstraZeneca plc (AZN) which gained 1.28% at USD 168.27 and had 98% buy orders, while Koninklijke Philips NV (PHG) declined 1.47% to USD 24.74 with a typical hold time of 83 days.
Beam Therapeutics is reaffirmed as a long-term buy due to its leadership in gene editing, particularly with its AATD treatment BEAM-302, expected to drive significant growth around 2028-2029. While the blockbuster potential of Risto-cel has been down...
Nord Precious Metals Mining Inc. welcomes the Canadian government's proposed Productivity Mega Deduction, which could allow immediate 100% tax deductions on qualifying equipment investments. This proposal supports Nord's ongoing engineering and permi...
Raydium, Solana's largest decentralized exchange, recorded its highest weekly revenue since mid-2025, driven by the integration of StonkFun's tokenized stock platform. This integration cut token launch costs by nearly 90%, sparking a surge in trading...
Technical analysis suggests Bitcoin may reach $220,000 by November 2027 if it follows its historical bull cycle pattern seen after major market bottoms. The pattern involves Bitcoin reclaiming and holding its 50-week moving average, which has histori...
Nu Holdings reported impressive Q2 2026 results with 55% year-over-year revenue growth and a 66% increase in net income, driven by expanding its user base from 65 million in 2022 to 139 million in 2026. The company achieved a 33% return on equity and...
